LUCINE SIGNED

Project "LUCINE" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

LUCINE is a revolutionary, clinically validated, solution for chronic pain diagnosis and management. Chronic pain is a global pandemic that affects 100 million Europeans. The management of pain is not adapted to the needs of the patients or the expectations of health professionals. When it becomes chronic, pain becomes an illness and has dramatic social, economic and public health impacts. Each year, approximately 1 in 5 Europeans are affected by chronic pain. Chronic pain adversely affects patient’s quality of life and can even limit a person’s movements, further interfering with daily activities. Health professionals lack the time and the tools to address a phenomenon as personal and subjective as pain. Still, chronic pain accounts for 22% of primary care physicians consults, with over a third of adult appointments involving a patient in chronic pain. The cost of pain at the European level can be estimated at € 441 billion. As a company, LUCINE is a leading innovator on pain diagnosis and management. LUCINE ́s customized mobile application is the first digital solution that can measure and analyse all facets of a patient’s pain, in 45 seconds. It utilises the smartphone’s camera and microphone to measure a patient’s pain levels through facial, postural, vocal and environmental recog¬nition. It provides an objective measurement of the patient’s pain level on a scale of 1 to 100. Moreover, LUCINE is the first “digital pharmacy” that offers personalised immersive healthcare solutions to relieve pain. Yet it relies on existing “devices” (smartphone, VR sets), by offering a variety of care adapted to the environment, pain levels and patient’s profile. Based on the data collected our system adapts the treatment to the tastes, attitudes, habits, and culture of the user. LUCINE’s products are targeting a large global market of € >350 billion represented by the over 1.5 billion individuals across the world who sufferfrom this type of pain.